MCED blood test demonstrates high specificity, strong predictive value, and increased early canc...
Автор: ecancer
Загружено: 2026-02-05
Просмотров: 1
Описание:
Dr Nima Nabavizadeh talks to ecancer at ESMO 2025 about data he presented.
The PATHFINDER II study evaluated the 'Galleri' multi-cancer early detection (MCED) blood test in over 35,000 adults aged 50 and older with no known cancer. Among 23,161 participants with one-year follow-up, 0.93% had a positive result. The test showed high specificity (99.6%), positive predictive value (61.6%), and accurate cancer origin prediction (91.7%).
Sensitivity was 73.7% for 12 major cancers and 40.4% overall. MCED testing detected 133 cancers, over half at early stages, and most without existing screening options. With few unnecessary invasive procedures (0.6%), MCED testing increased early cancer detection.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
